[pubmed] Benefit and danger from immunotherapy in myasthenia gravis
Posté : 05 févr. 2021 12:00
Neurol Sci. 2021 Feb 5. doi: 10.1007/s10072-021-05077-6. Online ahead of print.
ABSTRACT
In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
PMID:33543421 | DOI:10.1007/s10072-021-05077-6
Source: https://pubmed.ncbi.nlm.nih.gov/3354342 ... 9&v=2.14.2